A new peer-reviewed pharmacovigilance study published in Human Vaccines & Immunotherapeutics analyzed nearly 18,000 adverse event reports tied to the three FDA-approved RSV vaccines — Pfizer’s Abrysvo, GSK’s Arexvy, and Moderna’s mRESVIA. The results raise urgent concerns about vaccine safety, especially for seniors and pregnant women. A Pharmacovigilance Study with […]